20:55 , Apr 11, 2019 |  BC Week In Review  |  Company News

ADDF expands Alzheimer's diagnostic accelerator into digital space

With an additional $15 million in funding, the Alzheimer's Drug Discovery Foundation (ADDF) launched an initiative within its Diagnostics Accelerator program to advance the development of digital tools for Alzheimer's disease and related dementias. The...
23:22 , Apr 9, 2019 |  BC Extra  |  Company News

IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap. Prakash Raman,...
22:48 , Mar 27, 2019 |  BC Extra  |  Company News

Management tracks: Epic, Axcella, KalVista

Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....
23:13 , Mar 26, 2019 |  BC Extra  |  Company News

Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted. The hypoimmunogenic stem cells are derived...
17:30 , Mar 22, 2019 |  BC Week In Review  |  Company News

Germany to invest in CARB-X

Germany’s Federal Ministry of Education and Research (BMBF) plans to contribute €39 million ($44.3 million) to the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) over the next four years. BMBF will also provide €1 million...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
20:09 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)...
19:34 , Mar 1, 2019 |  BC Week In Review  |  Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) added six new organizations to its coalition, bringing its total membership to 10. With the new members, the non-profit aims to increase the number of early development antibacterial...
19:28 , Feb 26, 2019 |  BC Extra  |  Financial News

Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading...
00:35 , Feb 9, 2019 |  BC Extra  |  Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...